Dr. Luis E. Fayad MD Hematologist

Dr. Luis Fayad is a hematologist in Houston, Texas and is affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree from Universidad Catolica de Santiago de Guayaquil and has been in practice for 29 years. He is one of 46 doctors at University of Texas M.D. Anderson Cancer Center who specialize in Hematology.

Are you Dr. Fayad? Claim/Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Hematologist: General Hematology

Hospital Affiliation

University of Texas M.D. Anderson Cancer Center
Ranked #2 in Cancer

Education & Medical Training

Jackson Memorial Hospital/Jackson Health System
Residency, Internal Medicine, 1990–1993

University of Texas at Houston
Fellowship, Hematology, 1993–1994

University of Texas at Houston
Fellowship, Medical Oncology, 1994–1997

Universidad Catolica de Santiago de Guayaquil
Class of 1985

Certifications & Licensure

American Board of Internal Medicine
Certified in Hematology

American Board of Internal Medicine
Certified in Internal Medicine

American Board of Internal Medicine
Certified in Medical Oncology

FL State Medical License
Active through 2014

TX State Medical License
Active through 2014

AZ State Medical License
Active through 2014

Publications & Presentations

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
Esmaeli, B.,McLaughlin, P.,Pro, B.,Samaniego, F.,Gayed, I.,Hagemeister, F.,Romaguera, J.,Cabanillas, F.,Neelapu, S. S.,Banay, R.,Fayad, L.,Wayne Saville, M.,Kwak, L. W.

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang, M.,Fayad, L.,Cabanillas, F.,Hagemeister, F.,McLaughlin, P.,Rodriguez, M. A.,Kwak, L. W.,Zhou, Y.,Kantarjian, H.,Romaguera, J.

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
Oki, Y., Pro, B., Fayad, L.E., Romaguera, J., Samaniego, F., Hagemeister, F., Neelapu, S., McLaughlin, P., Goy, A., Younes, A.

See all 42 publications

Report a Correction — If you are aware of information on this page that is out of date or incorrect, please let us know.

Patient Advice & Support


See More
Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Nearby Hematologists

See all Hematologists near Houston, TX See all Hematologists in Texas

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.